| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
This prospective, double-blind, randomized study comprised patients who underwent abdominal operations. They were randomly allocated to receive intravenous fosaprepitant (NK1) or ondansetron (ONS) before anesthesia. No patient in the NKI group experienced vomiting after surgery; 20-30 % patients in the ONS group experienced vomiting. This difference was significant (at 0-2 h, 2-24 h, 24-48 h, and 48-72 h). During the study period, no significant differences existed between the NK1 and ONS groups in the incidence of PONV, complete response rate, rescue antiemetic use, nausea score, and VAS score for pain.
Additionally, NK1 was more effective than ONS in decreasing the incidence of vomiting after lower limb surgery with postoperative opioid administration as well.
|
